Stimulating effect of HIV-1 coat protein gp120 on corticotropin-releasing hormone and arginine vasopressin in the rat hypothalamus: Involvement of nitric oxide

Citation
A. Costa et al., Stimulating effect of HIV-1 coat protein gp120 on corticotropin-releasing hormone and arginine vasopressin in the rat hypothalamus: Involvement of nitric oxide, EXP NEUROL, 166(2), 2000, pp. 376-384
Citations number
55
Categorie Soggetti
Neurosciences & Behavoir
Journal title
EXPERIMENTAL NEUROLOGY
ISSN journal
00144886 → ACNP
Volume
166
Issue
2
Year of publication
2000
Pages
376 - 384
Database
ISI
SICI code
0014-4886(200012)166:2<376:SEOHCP>2.0.ZU;2-2
Abstract
Subjects with human immunodeficiency virus type 1 (HIV-1) infection display increased activity of the hypothalamo-pituitary-adrenal (HPA) axis, which may play a role in both HN-related neurodegenerative processes and disease progression. It has been speculated that the HIV coat protein gp120 may be responsible for these changes, and previous experimental evidence in both t ransgenic and nontransgenic mice supports this view. We speculated that one of the effects of gp120 in the CNS is to act within the hypothalamus to af fect both corticotropin-releasing hormone (CRH) and arginine vasopressin (A VP), the principal regulators of HPA axis. We therefore administered i.p. g p120 (100 ng/rat) or vehicle to male Wistar rats and then detected Fos prot ein (an index of neuronal activation), CRH, and AVP immunoreactivity in the cellular compartments of the hypothalamic paraventricular nucleus (PVN). I n addition, we tested the direct effect of various concentrations of gp120 on the release of CRH and AVP from rat hypothalamic explants maintained in vitro. Any modulation of gp120 effects by nitric oxide (NO) pathways was al so sought by coadministering i.p. to rats or adding to the hypothalamic pre parations the NO synthase inhibitor NG-methyl-L-arginine (L-NMMA). Gp120 in duced the expression of Fos protein in both the parvo- and the magnocellula r PVN, which was significantly attenuated by L-NMMA 10(-6) nM/L (P < 0.001 vs gp120 alone). Double immunochemistry showed costaining for Fos protein a nd CRH or AVP in the PVN following gp120; the number of double-labeled CRH and AVP cells for Fos protein was markedly reduced (P < 0.001) by coadminis tration of L-NMMA 10-6 nM/L. In the in vitro studies, addition of gp120 to the hypothalamic explants in the dose range of 10 pM-1 nM resulted in a cle ar stimulation of both CRH and AVP release (P < 0.05-0.001 compared to cont rol); in the presence of L-NMMA at 10-fold higher concentrations the stimul atory effect of gp120 on the release of both peptides was completely lost. It would therefore appear that gp120 activates CRH and AVP-producing neuron s in the hypothalamic PVN and stimulates the release of both peptides in vi tro via NO-dependent mechanisms. These findings, in line with previous evid ence, further suggest that the increased activity of the HPA axis associate d with HIV infection may be of central origin, due to the effects of gp120 on hypothalamic CRH and AVP release. (C) 2000 Academic Press.